Document Detail


Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.
MedLine Citation:
PMID:  22210187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: This study was to determine whether combination of the angiotensin II AT1 receptor blocker (ARB), candesartan cilexetil, and exercise training can prevent the development of high-fat diet-induced insulin resistance.
MAIN METHODS: F344/NSlc rats were fed normal chow diet or high-fat (HF) diet for 7 weeks. The HF-fed rats were either administered candesartan cilexetil (5 mg·kg(-1)·day(-1)), exercise-trained, or received a combination of these 2 treatments.
KEY FINDINGS: Oral glucose tolerance tests (OGTT) showed that combined treatment with candesartan cilexetil and exercise increased glucose tolerance as compared with each treatment alone in HF-fed rats. Moreover, euglycemic-hyperinsulinemic clamp analysis showed improvement in glucose infusion rate with exercise training or candesartan cilexetil treatment alone, and further improvement was observed with the combination treatment. Systolic blood pressure improved with candesartan cilexetil but not with exercise alone. Finally, Glut-4 protein expression in soleus muscle was decreased with HF diet, and the expression was increased by exercise and not candesartan cilexetil treatment.
SIGNIFICANCE: These results suggest that the combination of candesartan cilexetil and exercise training improves insulin resistance as compared with each treatment alone.
Authors:
Zhonghua Wang; Teruhiko Koike; Ping Li; Haiying Jiang; Yukie Natsume; Lan Mu; Tana Chen; Yoshiharu Oshida
Related Documents :
15997257 - Comparative study of the therapeutic effect of a systemic analgesic and transcutaneous ...
443887 - Hypercholesterolaemic arthropathy in primary biliary cirrhosis.
17917907 - Recurrent non-specific low-back pain in adolescents: the role of exercise.
17986497 - Hydrotherapy versus conventional land-based exercise for the management of patients wit...
8781867 - The specificity of strength training: the effect of posture.
11103657 - Exercise mitigates the association of abdominal obesity with high-density lipoprotein c...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-12-21
Journal Detail:
Title:  Life sciences     Volume:  90     ISSN:  1879-0631     ISO Abbreviation:  Life Sci.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-20     Completed Date:  2012-04-10     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0375521     Medline TA:  Life Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  322-7     Citation Subset:  IM    
Copyright Information:
Crown Copyright © 2011. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Animals
Benzimidazoles / administration & dosage*
Biphenyl Compounds / administration & dosage*
Blood Pressure / drug effects
Body Weight
Diet, High-Fat / adverse effects*
Glucose Tolerance Test
Glucose Transporter Type 4 / metabolism
Insulin / blood,  metabolism*,  pharmacology
Insulin Resistance / physiology*
Male
Muscle, Skeletal / metabolism
Physical Conditioning, Animal / physiology*
Rats
Rats, Inbred F344
Receptor, Angiotensin, Type 1 / metabolism*
Tetrazoles / administration & dosage*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Glucose Transporter Type 4; 0/Insulin; 0/Receptor, Angiotensin, Type 1; 0/Tetrazoles; R85M2X0D68/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients w...
Next Document:  Interaction of protein inhibitor of activated STAT 2 (PIAS2) with receptor of activated C kinase 1, ...